Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20  μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days.

CONCLUSION: A target Cmin ≥ 20 μg/mL might improve early clinical responses during the treatment of difficult MRSA infections using 12 mg/kg teicoplanin for five doses within the initial 3 days. PMID: 32641110 [PubMed - in process]
Source: BMC Pharmacology and Toxicology - Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research